Biotech startup raises $120 million in bid to reset the immune system
In a bid to help the immune system of autoimmune disease patients reset, a San Francisco startup startup has raised $120 ...
STAT1h
Patrizia Cavazzoni, head of FDA’s drug center, to leave the agency
Patrizia Cavazzoni, leader of the FDA's Center for Drug Evaluation and Research, is leaving the agency on Jan. 18.
Here’s Why ClearBridge Growth Strategy Sold Biogen (BIIB)
ClearBridge Investments, an investment management company, released its “ClearBridge Growth Strategy” fourth quarter 2024 ...
pharmaphorum3h
Ouro makes debut with $120m for autoimmune disease TCEs
A new biotech start-up – Ouro Medicines – launched today with $120 million in funding from a Series A and a plan to develop ...
manilatimes4h
Royalty Pharma to Highlight Accomplishments and Provide Business Update at 43rd Annual J.P. Morgan Healthcare Conference
Royalty Pharma will present at the 43rd Annual J.P. Morgan Healthcare Conference at 6:45 p.m. ET / 3:45 p.m. PT on January 14, 2025. The webcast will be accessible from Royalty Pharma's "Events” page ...
Royalty Pharma Announces Transformative Step in Company’s Evolution With Acquisition of its External Manager and $3 Billion Share Repurchase Program
Royalty Pharma plc to become an integrated company by acquiring its external manager, RP Management, LLCSignificant annual cash savings of ...
FierceBiotech4h
Chutes & Ladders—Amylyx preps for GLP-1 launch with new CCO
Dan Monahan, the exec who led Otsuka’s commercialization of Rexulti and Abilify Maintena, is taking command of the launch of ...
Ouro Medicines Launches To Define The Future Of Treatment For People With Immune-Mediated Diseases
Ouro Medicines, a biotechnology company developing immune reset therapeutics for people living with chronic immune-mediated diseases, today announced its launch with $120 million in funding. The ...
Wells Fargo Releases a Buy Rating on Regeneron (REGN)
Wells Fargo analyst Mohit Bansal assigned a Buy rating to Regeneron (REGN – Research Report) today and set a price target of $900.00. The ...
Alzheimer’s Drugs Eyed as Next Big Obesity-Like Opportunity
Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...
FierceBiotech6h
GSK-backed Ouro Medicines launches into T-cell engager space with $120M and a clinical-stage asset
Armed with $115 million and a clinical-stage asset, another player is emerging in the increasingly crowded T cell engager ...